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Abstract
Background. Diabetic nephropathy is a leading cause of
end-stage renal disease. Premature mortality is common in
patients with nephropathy, largely due to cardiovascular dis-
ease. Genetic variants implicated in macrovascular disease
are therefore excellent candidates to assess for association
with diabetic nephropathy. Recent genome-wide associa-
tion studies have identified a total of 15 single-nucleotide
polymorphisms (SNPs) that are reproducibly associated
with cardiovascular disease.
Methods. We initially assessed these SNPs for association
in UK type 1 diabetic patients with (cases; n = 597) and
without (controls; n = 502) nephropathy using iPLEXTM
and TaqMan R© assays. Replication studies were performed
with DNA genotyped in a total of 2668 individuals from
the British Isles.
Results. One SNP (rs4420638) on chromosome 19q13 was
found to be significantly associated with diabetic nephropa-
thy before (P = 0.0002) and after correction for multiple
testing (Pcorrected = 0.002). We replicated this finding in a
phenotypically similar case–control collection comprising
709 individuals with type 1 diabetes (P = 0.002; combined
P < 0.00001; OR = 1.54, 95% CI: 1.29–1.84).
Conclusions. Our case–control data suggest that
rs4420638, or a functional SNP in linkage disequilibrium
with this SNP, may be associated with diabetic nephropathy.
Keywords: apolipoprotein; association; diabetic nephropathy; genetics;
single-nucleotide polymorphisms
Introduction
Diabetic nephropathy is now the leading cause of end-stage
renal disease in developed countries [1], and is associated
with a 10-fold increased risk of macrovascular events [2].
Family studies have also shown that parents of individuals
with diabetic nephropathy are more susceptible to hyper-
tension, cardiovascular and cerebrovascular disease with
associated premature mortality [3,4]. Aggressive manage-
ment of hyperglycaemia, hypertension and cardiovascular
risk factors in individuals with diabetic nephropathy has
been recommended by the UK National Service Frame-
works for diabetes and renal services [5].
Diabetic nephropathy exhibits a multifactorial aetiology,
but determining definitive genetic risk factors has proved
challenging [6,7]. Several recent large-scale association
studies [8–10] have identified 15 single-nucleotide poly-
morphisms (SNPs) that demonstrated strong prior evidence
of association or were robustly replicated loci associated
with an increased risk of cardiovascular disease. We have
assessed these SNPs for association with diabetic nephropa-
thy in white individuals recruited as part of multicentre
collections in the British Isles.
Subjects and methods
Approval to conduct this study was obtained from the appropriate Research
Ethics Committees, and all those recruited provided written informed
consent. We obtained a total of 1099 genomic DNA samples from white,
unrelated individuals with type 1 diabetes diagnosed before 31 years of
age and who were insulin dependent from diagnosis. This population
includes individuals recruited as part of the UK Warren 3/Genetics of
Kidneys in Diabetes (GoKinD) collection [11]. Cases (n= 597) had onset
of persistent proteinuria (>0.5 g/24 h) at least 10 years after diagnosis
of diabetes with evidence of hypertension (>135/85 mmHg or treatment
with antihypertensive medication) and retinopathy. Controls (n = 502)
had diabetes for more than 15 years, with no evidence of renal disease and
were not prescribed antihypertensive medication.
Genomic DNA was also available from 709 white individuals of
Irish descent (parents and grandparents born in the island of Ireland)
[12]. Cases (n = 267) and controls (n = 442) were recruited with the
same inclusion/exclusion criteria as the UK population except that
these individuals had type 1 diabetes diagnosed before 35 years of age.
Similar clinical characteristics were observed for both groups (Table 1).
Genomic DNA was also available on 122 parent-affected offspring
trios derived from the UK Warren 3 collection; affected offspring were
recruited according to the same criteria as described above for UK cases
(http://www.diabetes.org.uk/en/About_us/News_Landing_Page/2865).
To minimize population heterogeneity, all recruited individuals were at
least second generation born in the British Isles, with similar phenotypic
inclusion criteria. Individuals with microalbuminuria were excluded from
all collections.
Genotyping and data analysis
Genotyping of genomic DNA samples was performed using the MassAR-
RAY iPLEXTM assay (Sequenom, San Diego, CA, USA) for 13 SNPs,
and a further two SNPs were genotyped using commercially available
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Table 1. Clinical characteristics of individuals with type 1 diabetes recruited to the case–control groups
UK collection All Ireland collection
Case Control Case Control
Number of individuals 597 502 267 442
Age at diagnosis (years) 14.5 (± 7.6) 15.6 (± 8.0) 16.7 (± 11.5) 15.0 (± 8.1)
BMI (kg/m2) 26.4 (± 4.8) 26.1 (± 4.2) 25.7 (± 4.8) 26.3 (± 4.2)
Duration of diabetes (years) 33.9 (± 9.3) 29.2 (± 9.1) 32.0 (± 9.3) 27.2 (± 9.3)
HbA1c (%) 8.6 (± 1.7) 8.2 (± 1.4) 10.6 (± 1.5) 9.5 (± 1.2)
Systolic BP (mmHg) 136.0 (± 30.4) 127.0 (± 15.5) 146.6 (± 20.1) 123.6 (± 13.6)
Diastolic BP (mmHg) 80.9 (± 11.6) 75.3 (± 8.5) 84.7 (± 10.5) 76.0 (± 6.9)
Table 2. Location, frequency and significance values of genotyped SNPs in the UK case–control dataset
Unique SNP identifier Alleles Chromosome location Affiliated gene Minor allele frequency (%) P value (genotype) P value (allele)
rs4420638 [8] G/A 19q13 APOC1 19 0.0003546 0.0001526b
rs17465637 [9] A/C 1q41 MIA3 28 0.02182 0.009071c
rs2383206a [10] A/G 9p21 None 49 0.4589 0.2898
rs10757274 [10] G/A 9p21 None 49 0.6197 0.3379
rs2943634 [9] A/C 2q36 None 34 0.5925 0.3094
rs6922269 [8,9] A/G 6q25 MTHFD1L 29 0.4176 0.3462
rs383830 [8] T/A 5q21 None 21 0.04421 0.3529
rs501120 [9] G/A 10q11 None 14 0.4317 0.5454
rs688034 [8] T/C 22q12 SEZ6L 34 0.4492 0.4682
rs17672135 [8] C/T 1q43 FMN2 12 0.7447 0.6367
rs17228212 [9] C/T 15q22 SMAD3 30 0.6222 0.662
rs8055236 [8] T/G 16q24 CDH13 20 0.9462 0.7458
rs599839a [9] G/A 1p13 PSRC1 22 0.9055 0.7927
rs1333049 [8,9] C/G 9p21 None 47 0.5752 0.7858
rs7250581 [8] A/G 19q12 None 20 0.7754 0.9058
aSNPs genotyped by TaqMan.
bPcorrected = 0.002.
cPcorrected = 0.1.
Initially, the genotypic test (2df, –model –cell 5) was used to provide a general test of association for the single phenotype (case/control) of diabetic
nephropathy. The basic allelic chi-square test (1df, –assoc) was used to provide asymptotic P-values. Adjustment for multiple testing was performed
using Bonferroni’s method.
TaqMan R© kits (Applied Biosystems, Warrington, UK), as previously de-
scribed [11]. Quality checks of genotyping data were performed, including
individual and SNP-based call rates, departures from the Hardy–Weinberg
equilibrium, duplicate error rates and Mendelian inconsistencies.
Statistical analysis
Analyses were performed using the standard tests implemented in PLINK
[13]. Initially, the genotypic test (2df, –model –cell 5) was used to provide
a general test of association for the single phenotype (case/control) of
diabetic nephropathy. The basic allelic chi-square test (1df, –assoc) was
used to provide asymptotic P-values and odds ratios (95% confidence
interval) for minor alleles. The level of statistical significance was set at
5%, and the adjustment for multiple testing was performed using Bon-
ferroni’s method. Allele counts from both case–control collections were
combined using a stratified analysis for Mantel–Haenszel odds ratio to
minimize potential confounding between populations. Haplotype analysis
was conducted where SNPs formed a haplotype block using 95% confi-
dence bounds on D′. The initial UK case–control collection had >80%
power to identify an allele with an odds ratio of at least 1.5, assuming a
minor allele frequency of 10% in controls.
Results
Prior to statistical analysis, nine individuals were removed
from the UK case–control dataset where no genotypes
were obtained for more than one SNP; remaining genotype
completion rates were >99%. Minor allele frequencies ex-
ceeded 10% for all variants (Table 2) and the distributions
of genotypes in cases and controls were consistent with the
Hardy–Weinberg equilibrium. Experimental controls were
as expected. Two SNPs demonstrated evidence for asso-
ciation with diabetic nephropathy in the UK case–control
collection, but only one remained significant after Bonfer-
roni correction for multiple testing; rs17465637 Pgenotype =
0.02; Pallele = 0.009; Pcorrected = 0.2 and rs4420638 Pgenotype
= 0.0004; Pallele = 0.0002; Pcorrected = 0.002, OR = 1.5
(95% CI: 1.2–1.9).
Statistically significant evidence for association was also
observed in a separate All Ireland population, providing
convincing support for the involvement of this novel SNP
in diabetic nephropathy (P= 0.002; Table 3). Combining
these two collections by stratified analysis revealed an odds
ratio of 1.54 (95% CI: 1.29–1.84; P< 0.00001). No signif-
icant distortion in transmission frequency was observed
for rs4420638 in families (P = 0.3). Consistent with pre-
vious findings, strong LD (D′ > 0.95) was observed for
three variants localized to chromosome 9p21 (rs10757274,
rs2383206, rs1333049); frequencies of estimated haplo-
types for these markers were similar in case and control
groups (data not shown). The two most commonly ob-
served haplotypes were AAG (47% versus 50%, P = 0.2)
and GGC (46% versus 46%, P= 0.9) in cases and controls,
respectively.
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Table 3. Genotype and allele data for rs4420638 in UK and All Ireland case–control collections
UK collection All Ireland collection
Case Control Case Control
Genotypes 355/209/26 346/141/7 171/81/15 322/111/8
Alleles 261/919 155/833 111/423 127/755
Minor allele frequency (%) 22.1 15.7 20.8 14.4
Unadjusted Pgenotype value 0.0004 0.004
Unadjusted Pallele value 0.0002 0.002
Pcorrected 0.002
Fig. 1. Genomic context of associated SNP with the position of rs4420638 highlighted by dashed line. SNPs depicted are those genotyped in the CEU
population in this region as part of HapMap project release 21.
Discussion
Utilizing a relatively large (n= 1099) collection of individ-
uals with type 1 diabetes with or without nephropathy, we
observed positive associations for two loci at the 5% level.
One marker (rs4420638) remained statistically significant
following stringent adjustment for multiple testing, and was
replicated in a second case–control collection. The lack of
statistically significant support in the family-based associa-
tion study may be due to the small sample size, or explained
by rs4420638 in linkage disequilibrium with the disease-
causing allele. Of note, we also found a non-significant
increase of the minor allele in diabetic nephropathy pa-
tients, compared to non-nephropathic controls, with type
2 diabetes from Northern Ireland (n= 494; 17.9% versus
14.6%). It is possible that the significant association iden-
tified in this study is due to susceptibility to cardiovascular
disease in patients with nephropathy rather than a shared
mechanism contributing to both end points. A large, long-
term prospective study, such as the FinnDiane cohort, may
ultimately be able to test the interaction between CVD, di-
abetic nephropathy and genotypes.
SNP rs17465637 (allele-based Puncorrected = 0.009) was
also genotyped in the All Ireland population to further
investigate the association of this marker with diabetic
nephropathy. The resultant allele-based P= 0.7056 sup-
ports the theory that this SNP is not strongly associated
with diabetic nephropathy in individuals with type 1 dia-
betes from the British Isles.
Genome-wide association studies [9] suggest strong LD
within this region of 19q13; however, the genomic region is
poorly mapped for genomic variation based on information
in online resources. Indeed, APOC1/APOE loci are poorly
tagged by the Affymetrix 500K chip [8]. The SNP statisti-
cally associated with diabetic nephropathy (rs4420638) is
linked to APOC1, but the adjacent region contains three
other APO genes (APOC2, APOC4, APOE) in close prox-
imity (Figure 1). APOC1 has been suggested to exacerbate
dyslipidaemia [14]. Increased apoCIII has been reported in
patients with chronic renal failure, and an increase in apoCI
has been specifically observed with diabetic nephropathy
[15]. Several studies have examined a limited number of
genetic variants in APOC2, APOC4 and APOE genes for
association with diabetic nephropathy [7]. It has been sug-
gested that rs4420638 co-inherits with APOE genotypes
[16], which are ∼14 kb away. Both statistically signifi-
cant association and a lack of association with nephropathy
have been observed for genetic profiles at the APOE locus
in individuals with diabetes [7]. Due to the lack of publicly
available SNP data in this region, extensive resequencing is
required to identify appropriate SNPs for genotyping. Fine
mapping of the adjacent genomic region and replication by
other groups will help to confirm this SNP as a genuine
susceptibility allele or part of an important haplotype.
In conclusion, we have identified a previously unreported
association of rs4420638 at 19q13 with diabetic nephropa-
thy in two type 1 diabetic populations from the British Isles.
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Abstract
Background. Coeliac disease is more frequent in IgA
nephropathy (IgAN) patients compared to the healthy pop-
ulation. Several hypotheses postulate that food antigens like
gluten may be involved in the onset of IgAN.
Methods. In this study, we used a recently developed
mucosal patch technique to evaluate the rectal mucosal
inflammatory reaction to gluten in patients with IgAN
(n = 27) compared to healthy subjects (n = 18). The rec-
tal mucosal production of nitric oxide (NO) and release
of myeloperoxidase (MPO) and eosinophil cationic protein
(ECP) were measured. Serum samples were analysed for
IgA and IgG antigliadin antibodies (AGA), IgA antibod-
ies against tissue transglutaminase and IgA endomysium
antibodies.
Results. Gluten reactivity, defined as increase in MPO
and/or NO after gluten exposure, was observed in 8 of 27
IgAN patients. The prevalence of HLA-DQ2 and DQ8 was
not increased among gluten-sensitive patients, and the total
prevalence among IgAN patients was the same as for the
normal population. An elevated serum IgA AGA response
was seen in 9 of 27 IgAN patients. The increase in IgA AGA
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